Paget's Disease and Breast Cancer: What You Need to Know
"A new study sheds light on treatment options for Paget's disease with invasive ductal carcinoma, offering hope for better outcomes."
Paget's disease of the breast (PD), a rare form of cancer affecting the nipple and areola, can be a diagnostic challenge. Often mistaken for benign skin conditions, early and accurate diagnosis is crucial. When PD occurs with invasive ductal carcinoma (IDC), it presents unique considerations for treatment and prognosis. This article breaks down a recent study that explores these considerations, providing clarity for those seeking information and guidance.
A study analyzed data from the Surveillance, Epidemiology, and End Results (SEER) program to investigate the clinical characteristics, treatment approaches, and survival outcomes of patients diagnosed with Paget's disease with invasive ductal carcinoma (PD-IDC). The research particularly focused on the role of surgical treatment options, aiming to identify factors that contribute to better patient outcomes.
Using SEER data from 2010-2013, the study compared patients with PD-IDC to those with IDC alone, examining differences in survival rates and the impact of various treatment strategies. The findings offer valuable insights into how PD-IDC affects prognosis and how surgical interventions can be optimized.
A Rare Breast Cancer Presentation
Paget's disease of the breast accounts for about 1% to 3% of all breast cancers, although another source reports a range of 1% to 4%. It occurs mostly in postmenopausal women and may present with nipple erythema, scaling, eczematous rash, ulceration, bleeding, pain, or itching. A 2022 retrospective review from the Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome examined 115 consecutive cases treated between 2000 and 2021.
Diagnosis and Treatment Require Individualization
Patients with mammary Paget disease most often undergo the same diagnostic evaluation, staging, and treatment used for other breast cancers. Surgical management remains controversial, partly because imaging may not reliably estimate the full extent of disease. Mastectomy has historically been considered standard, while breast-conserving surgery followed by radiotherapy has been investigated for selected patients.
From Velpeau to James Paget
The characteristic erythema and eczematous nipple changes were described by Velpeau in 1856, while James Paget described the disease in 1874. Historical scholarship continues to reassess the condition's origins through medieval surgical manuscripts and nineteenth-century clinical texts. One proposed explanation, the epidermotropic theory, holds that Paget cells arise in breast ducts and spread through the lactiferous sinuses to the nipple epidermis.
Key Findings: Unpacking the Research on Paget's Disease with Invasive Ductal Carcinoma
The study revealed several important insights: Patients with PD-IDC often present with more extensive lymph node involvement, larger tumor sizes, and higher-grade tumors compared to those with IDC alone. PD-IDC tumors are more likely to be hormone receptor-negative and HER2-positive. Despite these factors, patients with PD-IDC showed a better prognosis and lower mortality rates compared to the IDC group after adjusting for other variables.
- Better Prognosis: PD-IDC patients show improved survival compared to IDC patients.
- HER2 Impact: HER2-positive PD-IDC is linked to higher breast cancer-specific mortality.
- Surgery Options: Breast-conserving surgery with radiotherapy appears to be a feasible alternative to mastectomy.
- Lymph Node Biopsy: Sentinel lymph node biopsy should be considered for appropriate treatment.
An Evolving Evidence Base
Recent work on Paget's disease continues to examine how diagnosis, staging, treatment, and prognosis should be integrated. Because the condition is uncommon and clinically heterogeneous, much of the evidence is likely to come from retrospective studies, reviews, and selected patient series rather than large randomized trials. Treatment decisions therefore require careful interpretation of the available evidence and the individual patient's disease characteristics.
Where Management Can Fall Short
Paget's disease can be mistaken for a benign dermatologic condition, which may delay recognition and diagnosis. Surgical management is controversial, and a 2024 study specifically examined whether imaging reliably estimates disease extent. These limitations show why persistent or suspicious nipple changes require clinical assessment rather than being assumed to represent simple dermatitis.
Comparing Treatment Strategies
Mastectomy and breast-conserving surgery with radiotherapy represent different surgical approaches discussed in the management of Paget's disease. The available source material indicates that the choice is not settled by a single universal procedure, because surgical management remains controversial and disease extent can be difficult to estimate. Comparisons are therefore most meaningful when they account for the underlying in situ or invasive carcinoma and the reliability of preoperative assessment.
Moving Forward: What This Means for Patients and Future Research
This study offers a more optimistic outlook for individuals diagnosed with Paget's disease with invasive ductal carcinoma. The findings support considering breast-conserving surgery with radiotherapy as a potential alternative to mastectomy, and emphasize the importance of sentinel lymph node biopsy for appropriate staging and treatment planning.
Putting Diagnosis and Treatment Together
Paget's disease is an uncommon and often misdiagnosed breast malignancy that requires coordinated diagnosis, work-up, treatment, and prognostic assessment. Although mastectomy has been considered standard of care, several studies support breast-conserving surgery with radiotherapy as an alternative for selected patients. Research is also examining how estrogen receptor and HER2 expression, including clinical subtypes of invasive ductal carcinoma, may affect survival outcomes.
Questions for Future Research
Future research will likely focus on improving early recognition, defining disease extent more accurately, and identifying which patients can safely receive breast-conserving treatment. Studies may also clarify how tumor biology influences prognosis and treatment selection. Because Paget's disease is rare, progress will depend on carefully designed studies and broader clinical evidence.
A Rare Disease With Hidden Extent
Paget's disease is a rare cancer of the nipple–areola complex that is often associated with an underlying in situ or invasive carcinoma. This association creates a systemic clinical challenge: visible nipple changes may represent disease extending beyond the skin. Effective care therefore depends on recognizing the lesion and evaluating for associated breast carcinoma.
Biology Shapes Individual Experience
Recent research has examined HER2-overexpressing mammary Paget's disease combined with invasive ductal carcinoma, including the reported discordance between tumor size and lymph-node burden. A separate SEER 17 analysis evaluated the prognostic impact of estrogen receptor and HER2 expression in invasive ductal carcinoma with Paget's disease among patients diagnosed from 2010 onward. Case-based literature also describes a 60-year-old patient who presented with an eczematous lesion of the right nipple, illustrating how the condition may first appear as a localized skin change.
Further research is needed to refine treatment strategies and identify which patients are most likely to benefit from specific surgical approaches. Future studies should also investigate the molecular profiles of PD-IDC tumors to better understand their behavior and response to therapy. Additionally, more data is needed regarding systemic therapy.
Ultimately, a collaborative and standardized approach to managing PD-IDC is essential to optimize patient outcomes. By staying informed and working closely with their healthcare providers, individuals affected by this rare disease can make informed decisions about their treatment journey.